In the third part of this roundtable discussion, experts discuss the issues with data that AI must overcome. Pharmaceutical Executive recently brought together a group of experts to discuss the ...

New technology is making it easier for more companies to embrace telehealth, which in turn is providing more opportunities for pharma companies to interact with HCPs and patients. Peter Ax, founder ...

GLP-1s are the most discussed drug of 2024. While they were initially developed to treat diabetes, the drug’s ability to help with weight loss has made them extremely popular. So much so that in 2023, ...

These professionals in the healthcare marketing sector have been chosen by their peers for making big moves and taking on larger roles. The pharmaceutical industry is undergoing a transformative era, ...

The molecule is an investigational pre-clinical oral GLP-1 receptor agonist. Merck entered into an agreement with Hansoh Pharma in which the former company will obtain the global license agreement for ...

In this part of his Pharmaceutical Executive video interview, Peter Ax, CEO of UpScriptHealth, discusses the recent DEA extensions of telehealth for controlled substances and new treatment modalities ...

PharmaLex’s chief strategy officer discusses strategies to improve monetization for these drugs. Strategies for ensuring revenue from mature drugs are much more complex than with newer products, and ...

Amid the end of a national GLP-1 shortage, the FDA will now require all compounding, distributing, or dispensing of compounded tirzepatide injections to end within 90 days. The FDA has updated its ...

Approval of Steqeyma was based on a comprehensive evidence review, including a Phase III trial in moderate to severe plaque psoriasis. The FDA has approved Celltrion’s Steqeyma (ustekinumab-stba), a ...

In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA ...

The importance of expanding your pharma sales forecasting horizon beyond the US. Learn how to effectively navigate country-specific regulatory red flags. US-centric forecasts are often inadequate when ...